Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. More Details
Flawless balance sheet and overvalued.
Share Price & News
How has Cynata Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CYP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CYP's weekly volatility (9%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: CYP underperformed the Australian Biotechs industry which returned 8.8% over the past year.
Return vs Market: CYP underperformed the Australian Market which returned -1.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Cynata Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StThe Cynata Therapeutics (ASX:CYP) Share Price Is Up 248% And Shareholders Are Boasting About It
1 year ago | Simply Wall StAnalysts Expect Breakeven For Cynata Therapeutics Limited (ASX:CYP)
1 year ago | Simply Wall StWhat Type Of Shareholder Owns Cynata Therapeutics Limited's (ASX:CYP)?
Is Cynata Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CYP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CYP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CYP is unprofitable, so we can't compare its PE Ratio to the XX Biotechs industry average.
PE vs Market: CYP is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CYP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CYP is good value based on its PB Ratio (5.6x) compared to the AU Biotechs industry average (6.4x).
How is Cynata Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CYP's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if CYP's earnings are forecast to grow faster than the Australian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if CYP's revenue is forecast to grow faster than the Australian market.
High Growth Revenue: Insufficient data to determine if CYP's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CYP's Return on Equity is forecast to be high in 3 years time
How has Cynata Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CYP is currently unprofitable.
Growing Profit Margin: CYP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CYP is unprofitable, and losses have increased over the past 5 years at a rate of 11% per year.
Accelerating Growth: Unable to compare CYP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (9%).
Return on Equity
High ROE: CYP has a negative Return on Equity (-21.67%), as it is currently unprofitable.
How is Cynata Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CYP's short term assets (A$13.9M) exceed its short term liabilities (A$689.7K).
Long Term Liabilities: CYP has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: CYP is debt free.
Reducing Debt: CYP has no debt compared to 5 years ago when its debt to equity ratio was 0.4%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CYP has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CYP has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 14.9% each year
What is Cynata Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CYP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CYP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CYP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CYP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CYP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Ross MacDonald (62 yo)
Dr. Ross Alexander MacDonald, Ph.D., Grad Dip in Bus Admin serves as the Chief Executive Officer and Managing Director at Cynata Therapeutics Limited (formerly Eco Quest Limited). Dr. MacDonald served as t...
CEO Compensation Analysis
Compensation vs Market: Ross's total compensation ($USD334.29K) is about average for companies of similar size in the Australian market ($USD280.83K).
Compensation vs Earnings: Ross's compensation has been consistent with company performance over the past year.
|MD, CEO & Executive Director||no data||AU$454.17k||1.77% |
|Independent Non-Executive Chairman||0.25yr||AU$107.88k||0.066% |
|Independent Non-Executive Director||4.42yrs||AU$110.00k||0.15% |
|Non-Executive Director||7.25yrs||AU$55.00k||1.9% |
|Member of Scientific Advisory Board||no data||no data||no data|
|Independent Non-Executive Director||0.42yr||AU$2.29k||no data|
Experienced Board: CYP's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.7%.
Cynata Therapeutics Limited's company bio, employee growth, exchange listings and data sources
- Name: Cynata Therapeutics Limited
- Ticker: CYP
- Exchange: ASX
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$93.699m
- Shares outstanding: 117.12m
- Website: https://www.cynata.com
- Cynata Therapeutics Limited
- 62 Lygon Street
- Level 3
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CYP||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Dec 2007|
|CYP||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Dec 2007|
|CYYN.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Dec 2007|
|51S||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Dec 2007|
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The c...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/27 07:03|
|End of Day Share Price||2020/11/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.